| Literature DB >> 30429820 |
Stanislaw Szlufik1, Maria Kloda1,2, Andrzej Friedman1, Iwona Potrzebowska1,2, Kacper Gregier1, Tomasz Mandat3, Andrzej Przybyszewski4, Justyna Dutkiewicz1, Monika Figura1, Piotr Habela4, Dariusz Koziorowski1.
Abstract
Background: Subthalamic nucleus deep brain stimulation (STN-DBS) has been an established method in improvement of motor disabilities in Parkinson's disease (PD) patients. It has been also claimed to have an impact on balance and gait disorders in PD patients, but the previous results are conflicting. Objective: The aim of this prospective controlled study was to evaluate the impact of STN-DBS on balance disorders in PD patients in comparison with Best-Medical-Therapy (BMT) and Long-term-Post-Operative (POP) group.Entities:
Keywords: DBS (deep brain stimulation); Parkinson's disease; gait; instability analysis; neuromodulation
Year: 2018 PMID: 30429820 PMCID: PMC6220087 DOI: 10.3389/fneur.2018.00906
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Study population.
| Gender | 11 F, 9 M | 8 F, 12 M | 7 F, 8 M |
| Age at study beginning | 56.7 ± 15.4 years | 51.1 ± 15.3 years | 51.4 ± 8.7 years |
| Time of onset | 46.3 ± 15.1 years | 39.7 ± 13.3 years | 40.9 ± 8.3 years |
| Symptoms' duration time | 10.4 ± 4.9 years | 11.3 ± 3.9 years | 10.5 ± 3.5 years |
| Time of dyskinesia | 1.8 ± 2.6 hours daily | 4.9 ± 2.9 hours daily | 5.9 ± 2.6 hours daily |
| OFF time | 2.7 ± 1.3 hours daily | 4.6 ± 3.2 hours daily | 4.4 ± 1.8 hours daily |
| LEDD—Visit 1 | 1254.0 ± 511.6 mg | 1379.5 ± 510.0 mg | (pre-operative): 1273.2 ± 464.3 mg (post-operative): 585.4 ± 409.7 mg |
| LEDD—Visit 2 | 1564.0 ± 542.2 mg | 350.3 ± 262.2 mg | 555.7 ± 499.6 mg |
| LEDD—Visit 3 | 1558.3 ± 622.1 mg | 394.5 ± 319.2 mg | 762.9 ± 589.8 mg |
| UPDRS III OFF—Visit 1 | 32.3 pts | 34.1 pts | 39.5 pts |
| UPDRS III ON—Visit 1 | 12.8 pts | 11.5 pts | 10.2 pts |
| UPDRS III OFF—Visit 2 | 37.0 | 42.9 | 43.0 pts |
| UPDRS III ON—Visit 2 | 12.8 pts | 7.9 pts | 10.8 pts |
| UPDRS III OFF—Visit 3 | 41.7 | 45.1 pts | 47.2 pts |
| UPDRS III ON—Visit 3 | 12.8 pts | 9.3 pts | 11.4 pts |
p < 0.05.
Figure 1(A–F) Posturography and clinical balance tests' parameters in study groups (BMT, DBS, POP) in visits 1–3 (V1, V2, V3) *p < 0.05. (A) AP-CoP velocity (mm) with open eyes in Total-OFF phase in study groups (BMT, DBS, POP) in visits 1–3 (V1, V2, V3). (B) ML-CoP velocity (mm) with open eyes in Total-OFF phase in study groups (BMT, DBS, POP) in visits 1–3 (V1, V2, V3). (C) Perimeter (mm) with open eyes in Total-OFF phase in study groups (BMT, DBS, POP) in visits 1–3 (V1, V2, V3). (D) Perimeter (mm) with closed eyes in Total-OFF phase in study groups (BMT, DBS, POP) in visits 1–3 (V1, V2, V3). (E) Timed Up And Go test in Total-OFF phase in study groups (BMT, DBS, POP) in visits 1–3 (V1, V2, V3). (F) Tandem Walking Test in Total-OFF phase in study groups (BMT, DBS, POP) in visits 1–3 (V1, V2, V3).
Posturography and clinical balance tests' parameters in study groups: Δ = inter-visit differences.
| Δ | Δ | Δ | Δ | Δ | Δ | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase: Parameter: | ON | OFF | ON | OFF | ON | OFF | ON | OFF | ON | OFF | ON | OFF |
| Δ AP-CoP velocity [mm/s] /eyes open/ | 4.07 | 1.60 | 2.41 | 7.71 | −17.62 | −2.08 | 0.75 | 6.75 | 3.23 | 5.0 | −3.21 | −4.71 |
| Δ ML-CoP velocity [mm/s] /eyes open/ | 1.24 | 2.91 | 5.01 | 6.72 | −8.91 | −3.31 | 0.55 | 9.5 | 5.53 | 5.64 | −4.18 | −5.57 |
| Δ perimeter [mm] /eyes open/ | 101.3 | 81.84 | 132.9 | 279.9 | −505.4 | −101.3 | 26.75 | 297.9 | 162.0 | 204.9 | −135.5 | −175.6 |
| Δ ellipse area [mm2] /eyes open/ | 360.6 | 416.7 | 832.8 | 773.0 | −47.84 | −277.9 | 167.3 | 214.1 | 31.15 | 629.4 | −172.5 | −467.6 |
| Δ AP-CoP velocity [mm/s] /eyes closed/ | 5.49 | 3.09 | 0.06 | 5.13 | −17.76 | −3.49 | −2.35 | 16.4 | 1.91 | 7.14 | −3.40 | −5.5 |
| Δ ML-CoP velocity [mm/s] /eyes closed/ | 2.75 | 3.65 | 3.75 | 2.87 | −9.04 | −3.65 | −0.4 | 30.85 | 5.55 | 5.21 | −2.82 | −5.0 |
| Δ perimeter [mm] /eyes closed/ | 158.0 | 133.7 | 72.9 | 148.2 | −502.1 | −128.1 | −53.1 | 899.2 | 129.3 | 237.1 | −115.1 | −203.6 |
| Δ ellipse area [mm2]/eyes closed/ | 870.7 | 1058 | 400.2 | −299.5 | 583.5 | −515.5 | 89.45 | 1677 | 682.0 | 631.1 | −1269 | −1169 |
| Δ Timed Up And Go tests [sek] | −1.26 | −1.05 | 0.21 | −0.61 | 0.57 | −3.15 | 0.54 | −1.58 | 0.0 | 0.69 | 0.35 | 5.25 |
| Δ Dual Task—Timed Up And Go test [sek] | −0.91 | −1.83 | 0.23 | −0.35 | 0.85 | −8.23 | 0.20 | −0.75 | −0.56 | −1.49 | 1.30 | 5.98 |
| Δ Tandem Walking Test | −2.98 | −0.14 | 1.17 | 0.85 | 0.18 | −5.93 | −0.35 | 2.97 | −0.83 | −1.12 | 4.98 | 8.52 |
p < 0.05.